Journal article

Standard versus hypofractionated intensity-modulated radiotherapy for prostate cancer: assessing the impact on dose modulation and normal tissue effects when using patient-specific cancer biology

EJ Her, MA Ebert, A Kennedy, HM Reynolds, Y Sun, S Williams, A Haworth

PHYSICS IN MEDICINE AND BIOLOGY | IOP PUBLISHING LTD | Published : 2021

Abstract

Hypofractionation of prostate cancer radiotherapy achieves tumour control at lower total radiation doses, however, increased rectal and bladder toxicities have been observed. To realise the radiobiological advantage of hypofractionation whilst minimising harm, the potential reduction in dose to organs at risk was investigated for biofocused radiotherapy. Patient-specific tumour location and cell density information were derived from multiparametric imaging. Uniform-dose plans and biologically-optimised plans were generated for a standard schedule (78 Gy/39 fractions) and hypofractionated schedules (60 Gy/20 fractions and 36.25 Gy/5 fractions). Results showed that biologically-optimised plans..

View full abstract

Grants

Awarded by National Health and Medical Research Council


Funding Acknowledgements

This study was supported by grant APP1126955 from the National Health and Medical Research Council and an Australian Government Research Training Program Scholarship. Yu Sun is funded by a Melbourne International Research Scholarship, a Movember Young Investigator Grant through PCa Foundation of Australia and Cancer Therapeutics Top-up Funding. Dr Reynolds is funded by a Movember Young Investigator Grant through PCa Foundation of Australia's Research Program.